Tomasz Domoradzki

Mr. Tomasz Domoradzki

WIHE

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Beata Pajak-TarnackaBeata Pajak-Tarnacka
Beata Pajak-Tarnacka
ESE. Siwiak
E. Siwiak
MSM. Sołtyka
M. Sołtyka
APA. Priebe
A. Priebe
RZR. Zieliński
R. Zieliński
WPWaldemar Priebe
Waldemar Priebe
The ability of 2-deoxy-d-glucose (2-DG) to interfere with d-glucose metabolism demonstrates that nutrient and energy deprivation is an efficient tool to suppress cancer cell growth and survival. Acting as a d-glucose mimic, 2-DG inhibits glycolysis due to formation and intracellular accumulation of 2-deoxy-d-glucose-6-phosphate (2-DG6P), inhibiting the function of hexokinase and glucose-6-phosphate isomerase, and inducing cell death. In addition to glycolysis inhibition, other molecular processes are also affected by 2-DG. Attempts to improve 2-DG’s drug-like properties, its role as a potential adjuvant for other chemotherapeutics, and novel 2-DG analogs as promising new anticancer agents are discussed in this review.

Verified
Journal Article
Open access
PDF file
AJAnna Jaskiewicz
Anna Jaskiewicz
TDTomasz Domoradzki
Tomasz Domoradzki
Beata Pajak-TarnackaBeata Pajak-Tarnacka
Beata Pajak-Tarnacka
Muscle cachexia is one of the most critical unmet medical needs. Identifying the molecular background of cancer-induced muscle loss revealed a promising possibility of new therapeutic targets and new drug development. In this review, we will define the signal transducer and activator of transcription 3 (STAT3) protein’s role in the tumor formation process and summarize the role of STAT3 in skeletal muscle cachexia. Finally, we will discuss a vast therapeutic potential for the STAT3-inhibiting single-agent treatment innovation that, as the desired outcome, could block tumor growth and generally prevent muscle cachexia.

23 November 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
Beata Pajak-TarnackaBeata Pajak-Tarnacka
Beata Pajak-Tarnacka
ESEwelina Siwiak-Niedbalska
Ewelina Siwiak-Niedbalska
AJAnna Jaskiewicz
Anna Jaskiewicz
MSMaja Sołtyka
Maja Sołtyka
RZRafał Zieliński
Rafał Zieliński
WPWaldemar Priebe
Waldemar Priebe
Over the last decade, we have seen tremendous progress in research on 2-deoxy-D-glucose (2-DG) and its analogs. Clinical trials of 2-DG have demonstrated the challenges of using 2-DG as a monotherapy, due to its poor drug-like characteristics, leading researchers to focus on improving its bioavailability to tissue and organs. Novel 2-DG analogs such as WP1122 and others have revived the old concept of glycolysis inhibition as an effective anticancer strategy. Combined with other potent cytotoxic agents, inhibitors of glycolysis could synergistically eliminate cancer cells. We focused our efforts on the development of new combinations of anticancer agents coupled with 2-DG and its derivatives, targeting glioblastoma, which is in desperate need of novel approaches and therapeutic options and is particularly suited to glycolysis inhibition, due to its reliance on aerobic glycolysis. Herein, we present evidence that a combined treatment of 2-DG analogs and modulation of histone deacetylases (HDAC) activity via HDAC inhibitors (sodium butyrate and sodium valproate) exerts synergistic cytotoxic effects in glioblastoma U-87 and U-251 cells and represents a promising therapeutic strategy.

3 November 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
Beata Pajak-TarnackaBeata Pajak-Tarnacka
Beata Pajak-Tarnacka
ESEwelina Siwiak-Niedbalska
Ewelina Siwiak-Niedbalska
AJAnna Jaskiewicz
Anna Jaskiewicz
MSMaja Sołtyka
Maja Sołtyka
TDTomasz Domoradzki
Tomasz Domoradzki
Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults with a poor prognosis. Despite significant progress in drug development, the blood–brain barrier (BBB) continues to limit the use of novel chemotherapeutics. Thus, our attention has been focused on the design, synthesis, and testing of small-molecule anticancer agents that are able to penetrate the BBB. One such compound is the D-glucose analog, 2-deoxy-D-glucose (2-DG), which inhibits glycolysis and induces GBM cell death. 2-DG has already been tested in clinical trials but was not approved as a drug, in part due to inadequate pharmacokinetics. To improve the pharmacokinetic properties of 2-DG, a series of novel derivatives was synthesized. Herein, we report the biological effects of WP1234, a 2-ethylbutyric acid 3,6-diester of 2-DG that can potentially release 2-ethylbutyrate and 2-DG inside the cells when metabolized. Using biochemical assays and examining cell viability, proliferation, protein synthesis, and apoptosis induction, we assessed the cytotoxic potential of WP1234. WP1234 significantly reduced the viability of GBM cells in a dose- and time-dependent manner. The lactate and ATP synthesis assays confirmed the inhibition of glycolysis elicited by released 2-DG. Furthermore, an evaluation of histone deacetylases (HDAC) activity revealed that the 2-ethylbutyrate action resulted in HDAC inhibition. Overall, these results demonstrated that WP1234 is a bifunctional molecule with promising anticancer potential. Further experiments in animal models and toxicology studies are needed to evaluate the efficacy and safety of this new 2-DG derivative.

1 March 2022 in Histochemistry and Cell Biology
Verified
Journal Article
Closed access
PDF file
MBMaciej Błaszczyk
Maciej Błaszczyk
MGMałgorzata Gajewska
Małgorzata Gajewska
MDMarta Dymowska
Marta Dymowska
AMAlicja Majewska
Alicja Majewska
TDTomasz Domoradzki
Tomasz Domoradzki
Katarzyna Grzelkowska-KowalczykKatarzyna Grzelkowska-Kowalczyk
Katarzyna Grzelkowska-Kowalczyk

30 December 2021 in Journal of Applied Genetics
Verified
Journal Article
Open access
PDF file
TDTomasz Domoradzki
Tomasz Domoradzki
PGPiotr Grochowski
Piotr Grochowski
AJAnna Jaskiewicz
Anna Jaskiewicz
Beata Pajak-TarnackaBeata Pajak-Tarnacka
Beata Pajak-Tarnacka
Our concerns have been raised about whether prolonged exposure to ammunition-related chemicals could correlate with genomic instability predisposing to lung carcinogenesis. The group of professional soldiers engaged in routine ammunition analysis and its explosive properties testing. To assess the presence of an innate genetic profile, DNA isolated from swabs was analyzed with LungCarta and HS Lung Panels and MassARRAY Analyzer 4 mass spectrometry. The presence of new somatic single nucleotide polymorphisms (SNPs) was detected with liquid biopsy technique and circulating cell-free DNA (ccfDNA) isolation, which was further analyzed with UltraSeek Lung Panel. Both genetic profiles obtained for each individual were compared. Genetic analysis revealed that in professional soldiers with long-term exposure to ammunition-related toxic chemicals, new SNPs in genes related to lung carcinogenesis are present. The preliminary data indicate that using modern molecular techniques could be a valuable tool for monitoring the genome instability in context of occupational risk of harmful volatile toxic compounds and improving personnel safety. The analyzed group will be further enlarged, and follow-up studies will be continued.